As a scientist, he has published more than 420 scientific articles in peer-reviewed scientific journals, which have been cited more than 30,000-times (h-index:91, Google Open Scholar).
LONDON, UNITED KINGDOM, November 29, 2018 /24-7PressRelease/ -- Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to present Dr. Christoph Thiemermann with the Albert Nelson Marquis Lifetime Achievement Award. An accomplished listee, Dr. Thiemermann celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Utilizing more than three decades of professional experience, Dr. Thiemermann is a distinguished educator and scientist who has been serving the William Harvey Research Institute, which is part of Queen Mary University of London (QMUL), for the majority of his career. Currently excelling as the chief executive officer of William Harvey Research (WHR) Limited, an executive committee member of the WHR Institute, a professor of pharmacology at QMUL and the Centre Lead for Translational Medicine & Therapeutics at the WHR Institute, he previously held various roles within the WHR Institute dating back to 1987. Previously, he worked for the WHR Institute/QMUL as a visiting scientist, senior scientist and reader in pharmacology. Dr. Thiemermann began his career as a research scientist at the Institute of Pharmacology in Dusseldorf, Germany, in 1986.
Dr. Thiemermann has a strong research track record in cardiovascular disease (acute medicine, renal disease, shock) with a specific expertise in target discovery, pharmacology and translational medicine. Recent successes have been phase II RCTs evaluating the effects of pentoxiphylline in patients with chronic kidney disease (on dialysis) and the repositioning of the antimalarial drug artesunate for patients with severe haemorrhage and organ failure (ongoing). His research was recognized by awards of the British Pharmacological Society (1994), the Surgical Infection Society Europe (1999) and the Menarini-Award for CV Research (2001). Over the years, Dr. Thiemermann's research has been generously supported by the European Union, the Medical Research Council, Kidney Research UK and William Harvey Research Foundation, Barts and the London Charity (BLC) and the National Institute for Health Research (NIHR).
As an educator, he has supervised more than 25 PhD-students, many of which have become leaders in their chosen fields of endeavour (medicine/research/business/regulatory affairs). Together with Mauro Perretti, he has developed the Module Business & Pharmacology for the BSc in Pharmacology of QMUL, and serves as a mentor for QMUL, the Academy of Sciences and the NIHR.
As a scientist, he has published more than 420 scientific articles in peer-reviewed scientific journals, which have been cited more than 30,000-times (h-index:91, Google Open Scholar). He is a Fellow of the Academy of Medical Sciences of the United Kingdom (since 2003), where he serves on the Nomination Committee (Pharmacology, Physiology & Neuroscience), a Member of the Helix Group of the Academy (since 2017), a Fellow of the British Pharmacological Society (since 2005), a Foreign Life Peer Member of the Academy of Sciences of Portugal (Lisboa) (since 2003), a Member/Deputy Chair and Chair of the Fellowships Committee of the NIHR (2008-2018), Member of the Training Implementation Group of the NIHR (since 2017), Past-President of the European Shock Society (presidency 2008-2011), Member of the Executive Council of the World Federation of Shock Societies (since 2008), Senior Associate Editor (Europe) of the Journal Shock (2003-17) and an Associate Editor of Frontiers in Immunology (Inflammation) (since 2017).
Alongside his primary endeavors, Dr. Thiemermann completed a senior fellowship at the British Heart Foundation in London for five years. Dr. Thiemermann held the post of visiting professor of pharmacology at the University of Sunderland in England for an additional five years.
To prepare for his career, Dr. Thiemermann pursued formal education at the University of Cologne, where he registered as a physician in 1986 and earned a Doctor of Medicine in 1987. He subsequently attended the University of London in 1991, graduating with a Doctor of Philosophy under the supervision of the Nobel Laureate Professor Sir John Vane, FRS. As a testament to his success, Dr. Thiemermann was selected for inclusion in the 63rd edition of Who's Who in America, as well as multiple editions of Who's Who in Medicine and Healthcare, Who's Who in Science and Engineering, and Who's Who in the World.
In recognition of outstanding contributions to his profession and the Marquis Who's Who community, Dr. Thiemermann has been featured on the Albert Nelson Marquis Lifetime Achievement website. Please visit www.ltachievers.com for more information about this honor.
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® now publishes many Who's Who titles, including Who's Who in America®, Who's Who in the World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #